{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:39:46Z","timestamp":1792636786657,"version":"4.5.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clgc.2026.102525","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:23:54Z","timestamp":1772583834000},"page":"102525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessing Treatment Outcomes of Patients Undergoing Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5241-309X","authenticated-orcid":false,"given":"Hal","family":"Rives","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2696-0018","authenticated-orcid":false,"given":"Jordan","family":"Fredette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fern","family":"Anari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Ghatalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1423-5295","authenticated-orcid":false,"given":"Daniel M","family":"Geynisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R","family":"Plimack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1475-6477","authenticated-orcid":false,"given":"Matthew","family":"Zibelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102525_bib0001","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"issue":"29","key":"10.1016\/j.clgc.2026.102525_bib0002","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102525_bib0003","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2026.102525_bib0004","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.clgc.2026.102525_bib0005","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1188\/21.CJON.E1-E9","article-title":"Enfortumab vedotin: nursing perspectives on the management of adverse events in patients with locally advanced or metastatic urothelial carcinoma","volume":"25","author":"Pace","year":"2021","journal-title":"Clin J Oncol Nurs"},{"issue":"22","key":"10.1016\/j.clgc.2026.102525_bib0006","first-page":"2433","article-title":"Primary results of EV-301: a phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma","volume":"39","author":"Powles","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102525_bib0007","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2026.102525_bib0008","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2147\/CMAR.S424070","article-title":"Effect of enfortumab vedotin dose adjustment on efficacy in metastatic urothelial carcinoma: a retrospective single-center experience","volume":"15","author":"Clennon","year":"2023","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.clgc.2026.102525_bib0009","doi-asserted-by":"crossref","first-page":"411","DOI":"10.21873\/invivo.13843","article-title":"Impact of relative dose intensity of enfortumab vedotin for advanced urothelial carcinoma","volume":"39","author":"Furubayashi","year":"2025","journal-title":"In Vivo"},{"key":"10.1016\/j.clgc.2026.102525_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102326","article-title":"Impact of initial relative dose intensity on tumor response and survival outcomes in enfortumab vedotin monotherapy for previously treated advanced urothelial carcinoma: a real-world analysis from a multicenter study","volume":"23","author":"Miyake","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2026.102525_bib0011","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2024.42.16_suppl.4503","article-title":"Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer","volume":"42","author":"Petrylak","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732600025X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732600025X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:29:27Z","timestamp":1778941767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732600025X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S155876732600025X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102525","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing Treatment Outcomes of Patients Undergoing Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102525"}}